Thursday, January 19, 2023, San Francisco, California, 6:15 PM – 7:45 PM Pacific Time (9:15 PM – 10:45 PM Eastern Time)

Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Gastroesophageal Cancers

Part 2 of a 3-Part CME Symposium Series Held in Conjunction with the 2023 ASCO Gastrointestinal Cancers Symposium

Location
San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600

Program Schedule — Pacific Time
5:45 PM – 6:15 PM — Registration and Dinner
6:15 PM – 7:45 PM — Educational Meeting

Meeting Room
Golden Gate Ballroom — Salon A (B2 Level)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Francisco, preregistration is required as seating is limited.  
 
Faculty
Yelena Y Janjigian, MD
Associate Professor
Chief of Gastrointestinal Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Florian Lordick, MD, PhD
Full Professor of Medicine at the University
of Leipzig
Director of the University Cancer Center
Head of Department of Oncology
Leipzig University
Leipzig, Germany


Zev Wainberg, MD, MSc
Co-Director, GI Oncology Program
Director of Early Phase Clinical Research
Jonsson Comprehensive Cancer Center
UCLA School of Medicine
Los Angeles, California

Moderator
Samuel J Klempner, MD
Associate Professor
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts


This activity is supported by educational grants from Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, and Lilly.
Program Schedule — Pacific Time
5:45 PM – 6:15 PM — Registration and Dinner Buffet
6:15 PM – 7:45 PM — Educational Meeting

MODULE 1: Optimizing the Selection of Therapy for Newly Diagnosed Advanced Gastric or Gastroesophageal Junction (GEJ) Cancer — Dr Klempner

  • Design, eligibility criteria and key efficacy and safety endpoints evaluated in the Phase III CheckMate 649 study comparing first-line nivolumab/chemotherapy or nivolumab/ipilimumab to chemotherapy alone for advanced gastroesophageal adenocarcinoma
  • Major efficacy and safety findings reported from the CheckMate 649 trial; impact of PD-L1 expression on outcomes
  • FDA-approved indication for nivolumab in combination with chemotherapy as first-line treatment and optimal incorporation into current management algorithms
  • Emerging findings from the Phase III KEYNOTE-859 study demonstrating a statistically significant improvement in overall survival with first-line pembrolizumab and chemotherapy compared to chemotherapy alone for advanced gastric/GEJ adenocarcinoma
  • Frequency of microsatellite instability-high (MSI-H) gastroesophageal adenocarcinoma; implications for current clinical care
  • Published and emerging findings with immune checkpoint inhibitors as neoadjuvant therapy for resectable MSI-H gastric or GEJ adenocarcinoma

MODULE 2: Current Considerations in the Treatment of HER2-Positive Advanced Gastric/GEJ Adenocarcinoma — Dr Janjigian

  • Frequency of HER2 amplification in advanced gastric/GEJ cancer
  • Principal outcomes from the Phase III KEYNOTE-811 trial supporting the use of first-line pembrolizumab/trastuzumab/chemotherapy for metastatic HER2-positive gastric/GEJ adenocarcinoma
  • Published efficacy and safety data with trastuzumab deruxtecan (T-DXd) for Asian (DESTINY-Gastric01 trial) and Western (DESTINY-Gastric02 trial) patients with progressive HER2-positive gastric/GEJ cancer
  • Spectrum, incidence and severity of toxicities, including interstitial lung disease, with T-DXd for gastric/GEJ cancer
  • FDA approval for T-DXd; optimal sequencing for patients with progressive HER2-positive disease
  • Ongoing clinical trials (eg, DESTINY-Gastric03, DESTINY-Gastric04) attempting to further define the role of T-DXd in gastric/GEJ cancer
  • Other promising agents/strategies in clinical development for HER2-positive gastroesophageal cancers

MODULE 3: Selection and Sequencing of Therapy for Relapsed/Refractory Gastric/GEJ Cancer; Novel Investigational Approaches — Prof Lordick

  • Published findings with and optimal integration of ramucirumab into current clinical algorithms for metastatic gastric/GEJ cancer; role of this agent for patients experiencing disease progression on an immune checkpoint inhibitor
  • Rationale for, available data with and ongoing investigation of novel combination approaches (eg, ramucirumab with TAS-102 or anti-PD-1 antibodies)
  • Biologic rationale for targeting claudin 18.2 in gastric/GEJ cancer
  • Mechanism of action of and early efficacy and safety data with zolbetuximab for advanced gastric/GEJ adenocarcinoma with claudin 18.2 expression
  • Emerging positive findings from the Phase III SPOTLIGHT and GLOW trials of first-line zolbetuximab in combination with chemotherapy for patients with claudin 18.2-positive metastatic gastric/GEJ cancer
  • Mechanism of action of bemarituzumab; available efficacy and safety data with and ongoing Phase III evaluation of first-line bemarituzumab/chemotherapy for FGFR2b-positive metastatic gastric/GEJ cancer
  • Other promising novel agents and strategies under investigation for HER2-negative gastric/GEJ cancer

MODULE 4: Current Approaches to the Management of Esophageal Cancer — Dr Wainberg

  • Clinical and biologic factors affecting the choice of therapy for patients with esophageal cancer
  • Design, eligibility criteria and primary and secondary endpoints of the Phase III CheckMate 577 study evaluating nivolumab as adjuvant therapy for patients with resected esophageal or GEJ cancer
  • Available efficacy and safety outcomes from the CheckMate 577 trial; FDA approval of and patient selection for adjuvant nivolumab
  • Published data from the Phase III CheckMate 648 study of nivolumab/chemotherapy and nivolumab/ipilimumab versus chemotherapy alone for advanced squamous cell carcinoma of the esophagus; recent FDA approval of these regimens
  • Major findings from the Phase III KEYNOTE-590 study evaluating first-line pembrolizumab combined with chemotherapy versus chemotherapy alone for advanced esophageal cancer; current role in clinical practice
  • Other promising immune checkpoint inhibitor-based strategies for localized or advanced esophageal cancer

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of gastrointestinal cancers.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Use HER2 status, PD-L1 combined positive score, microsatellite instability status, clinical factors and patient preferences to personalize the selection of first-line therapy for patients with locally advanced or metastatic gastric, gastroesophageal junction (GEJ) and esophageal cancer.
  • Describe published and emerging research data with the use of anti-PD-1/PD-L1 antibodies alone or in combination with other systemic therapies for the management of gastric, GEJ and esophageal cancer, and optimally integrate these strategies into the treatment algorithm.
  • Incorporate available therapeutic agents and regimens into the management of HER2-negative metastatic gastric, GEJ and esophageal cancer that has progressed on front-line therapy.
  • Appraise clinical trial findings with and discern the clinical applicability of adjuvant anti-PD-1 antibody therapy for patients with resected esophageal/GEJ cancer who have received neoadjuvant chemoradiation therapy and have residual pathologic disease.
  • Recall available data with novel HER2-targeted agents and strategies for newly diagnosed and previously treated HER2-overexpressing gastric/GEJ cancer, and identify candidates who may be appropriate for these approaches.
  • Recognize common and rare side effects associated with approved and investigational agents for gastroesophageal cancer, and apply this information to develop appropriate and effective supportive management plans.
  • Review the rationale for, available and emerging data with and ongoing studies evaluating novel agents and strategies for gastroesophageal cancers, and effectively prioritize clinical trial opportunities for eligible patients.

CME Credit Form
A CME credit link will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr JanjigianConsulting Agreements: AmerisourceBergen, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Basilea Pharmaceutica Ltd, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Geneos Therapeutics, GSK, Imugene, Lilly, Lynx Health LLC, Merck, Merck Serono, Mersana Therapeutics Inc, Michael J Hennessy Associates Inc, Pfizer Inc, Rgenix, Seagen Inc, Silverback Therapeutics, Zymeworks Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Lilly, Merck, Rgenix; Nonrelevant Financial Relationship: Imedex, Paradigm Medical Communications, PeerView Institute. Prof LordickConsulting Agreements: Amgen Inc, Astellas, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Lilly, Merck Sharp & Dohme LLC, Novartis, Roche Laboratories Inc; Contracted Research: Bristol-Myers Squibb Company, Gilead Sciences Inc; Data and Safety Monitoring Board/Committee: BioNTech AG; Speakers Bureau: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Incyte Corporation, Lilly, Merck Serono, Merck Sharp & Dohme LLC, Novartis, Roche Laboratories Inc, Servier Pharmaceuticals LLC; Nonrelevant Financial Relationship: Imedex, Medscape, MedUpdate, Streamedup. Dr WainbergAdvisory Committee and Consulting Agreements: Arcus Biosciences, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc; Contracted Research: Arcus Biosciences, Bristol-Myers Squibb Company, Plexxikon Inc; Data and Safety Monitoring Board/Committee: Daiichi Sankyo Inc, Pfizer Inc.

MODERATORSamuel J Klempner, MDAdvisory Committee: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Exact Sciences Corporation, Lilly, Merck, Mersana Therapeutics Inc, Novartis, Sanofi; Data and Safety Monitoring Board/Committee: Mersana Therapeutics Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, and Lilly.

San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600

Meeting Room
Golden Gate Ballroom — Salon A (B2 Level)

Directions
The San Francisco Marriott Marquis is located just 2 blocks (less than 0.2 miles) from the Moscone Convention Center, where the 2023 ASCO Gastrointestinal Cancers Symposium is taking place.

 
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of gastrointestinal cancers.

​ ​
IN-PERSON registration for clinicians in practice/healthcare professionals
Thank you for your interest in our CME program. At this time online preregistration is closed for this in-person event. SEATS ARE STILL AVAILABLE FOR THIS SESSION. Our onsite registration desk will be open at 5:45 PM PST on Thursday, January 19th. If you are interested in attending, please visit our registration desk located outside the Gold Gate Ballroom – Salon A (B2 Level) of the San Francisco Marriott Marquis hotel (780 Mission Street) within walking distance of the Moscone Convention Center (2 street blocks).

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

NOTICE:
Registration for this event is independent of registration for the 2023 ASCO GI Symposium.

LIVE WEBCAST registration for all professionals

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

 

Not official events of the 2023 ASCO Gastrointestinal Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.